CTOs on the Move

Landmark Bio

www.landmarkbio.com

 
Formerly known as the new center for advanced biological innovation and manufacturing (or “CABIM”), Landmark Bio, PBLLC is a public benefit limited liability company that was formed to advance the development of transformative new medicines by translating today`s cutting-edge research into tomorrow`s breakthrough therapies. The cross-sector partnership harnesses world-leading expertise to accelerate fast-emerging and promising science, the challenges of which are daunting for any single institution to tackle alone. Board members include leaders from Harvard University, Massachusetts Institute of Technology (MIT), FUJIFILM Diosynth Biotechnologies (FDB), Cytiva, and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Gregg Nyberg
Chief Technology Officer Profile

Similar Companies

Bio-Solutions Corporation

Bio-Solutions Corp, Owns and Markets Type2 Defense(TM), a glucose control dietary supplement powder formulated to support healthy glucose levels in addition to maintaining healthy blood pressure.   The company believes that there is a growing Diabetic target market place that lacks adequate healthy tools to maintain healthy blood glucose levels. Type2 Defense is a powder blend of natural ingredients that has been developed to maintain healthy blood glucose levels.

Trellis Bioscience

Trellis Bioscience is a leader in identifying rare protective antibodies by screening human blood cells.

BioStar Systems

BioStar Systems is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Flame Biosciences

Flame Biosciences is a clinical stage company focused on the research, development and commercialization of transformative therapies for cancer and other inflammatory conditions.

BiOptix

BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements.